Press Releases

Cellaviva delivers stem cells to treat serious blood disease

Cellaviva has released umbilical cord blood stem cells to Denmark’s leading hospital. A sibling of the child whose umbilical cord blood has been stored in Cellaviva’s biobank, suffers from a serious blood disorder that will be treated with stem cells at the Hematology Department at Rigshospitalet.

Cellaviva Sverige April 2, 2022

Recruitment start for the ProTrans study for treatment of COVID-19

ProTrans is given with the aim of reducing hyper-inflammation within the lungs. The goal of the treatment is to shorten hospital stay and time for rehabilitation and save lives.

Cellaviva Sverige May 21, 2021

Pediatric diabetes study with stem cells approved

Uppsala University Hospital and the principal investigator, Professor Per-Ola Carlsson, have been granted approval from the Medical Products Agency and the Swedish Ethical Review Authority to conduct a clinical drug trial with ProTrans™ to treat children and adolescents with type-1 diabetes. The study is a phase I / II study with a total of 66 patients.

Cellaviva Sverige April 27, 2021

Canadian Trial for ProTrans in COVID-19

TUE, FEB 02, 2021 15:50 CET NextCell Pharma AB (“NextCell”) today announces that Health Canada and the McGill University Health Centre Research Ethics Board have authorized the clinical trial entitled...

Cellaviva Sverige February 2, 2021

ProTrans stem cells approved for clinical trials in COVID-19 patients

NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the...

Cellaviva Sverige October 22, 2020

Presentation of the positive results from ProTrans-2

NextCell Pharma AB (“NextCell”) announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson…

Cellaviva Sverige September 10, 2020

ProTrans shows significant effect in Diabetes

Cellaviva's parent company NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved...

Cellaviva Sverige September 8, 2020

NextCell approved for trading on Nasdaq First North

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading…

Cellaviva Sverige July 6, 2020

NextCell Pharma AB’s rights issue heavily oversubscribed

The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the…

Cellaviva Sverige June 24, 2020

NextCell's phase II study is completed – a phase III is being prepared

NextCell Pharma AB (“NextCell”) announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is…

Cellaviva Sverige June 9, 2020

NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July

The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing…

Cellaviva Sverige June 3, 2020

Invited to panel discussion; Post-Covid-19 world

NextCell Pharma AB (“NextCell”) has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare – new challenges and main problems”. Doctor…

Cellaviva Sverige May 28, 2020